Precision Diagnostics Signs Research Collaboration Agreement with the University of Oxford’s SerenOx Project to Advance Precision Oncology in Asia-Pacific
Precision Diagnostics has signed a Research Collaboration Agreement with the University of Oxford’s SerenOx Project, marking a significant milestone in advancing precision oncology research, liquid biopsy innovation, and genomic medicine across the Asia-Pacific (APAC) region.
The agreement was formalised with Professor Anna Schuh, Clinical Director of Molecular Diagnostics at the University of Oxford and leader of the SerenOx Project. Precision Diagnostics is honoured to enter into this exclusive APAC partnership, which aims to bring cutting-edge genomic science closer to clinicians, researchers, healthcare systems, and patients across the region.
Scientific Leadership
Professor Schuh is a distinguished clinical haematologist and internationally recognised clinician-scientist in molecular diagnostics, translational cancer genomics, and liquid biopsy technologies. She also co-leads Genomics England’s Pan-Cancer and Molecular Oncology community, which focuses on understanding genomic variation across more than 200 cancer types, further underscoring the breadth and impact of her work in precision oncology.
This collaboration brings together the University of Oxford’s pioneering genomic research and Precision Diagnostics’ expertise in translating genomic science into clinically meaningful applications. Together, the organisations aim to accelerate the development, validation, clinical translation, and governance of innovative technologies that support earlier disease detection, improved disease monitoring, and more personalised patient care across APAC.
Advancing Liquid Biopsy Technologies & Cell-Free DNA Sequencing
A central focus of the collaboration will be the advancement of cell-free DNA technologies for precision oncology. By combining Oxford’s scientific leadership with Precision Diagnostics’ regional clinical network and precision medicine expertise, the partnership seeks to support the responsible evaluation, future adoption, and clinical implementation of next-generation genomic innovation across Asia-Pacific.
The collaboration builds on the pioneering work of Professor Schuh and her research team, including their recent publication in Nature Communications describing a multimodal whole-genome TET-Assisted Pyridine Borane Sequencing platform. This platform enables DNA methylation, copy number alterations, and somatic mutations to be analysed from a single cell-free DNA sample. Unlike conventional bisulfite sequencing, TAPS preserves DNA integrity while generating highly sensitive, non-invasive, and clinically relevant genomic insights.
Translating Research into Clinical Practice
Through this Research Collaboration Agreement, Precision Diagnostics and the University of Oxford’s SerenOx Project aim to strengthen translational research that connects scientific discovery with real-world clinical application, while supporting robust clinical governance, responsible implementation, and evidence-based precision oncology pathways.
The agreement further strengthens Precision Diagnostics’ portfolio of international scientific partnerships and reinforces its mission to advance evidence-based precision medicine through research, innovation, clinical translation, and strategic global collaboration.
About the University of Oxford’s SerenOx Project
The University of Oxford’s SerenOx MCED Project is dedicated to advancing translational genomics through innovative liquid biopsy technologies. Led by Professor Anna Schuh, the project focuses on developing highly sensitive cell-free DNA-based approaches for earlier disease detection, disease monitoring, and personalised patient management, with the goal of translating cutting-edge genomic research into clinical practice.
About Precision Diagnostics
Precision Diagnostics is a precision medicine and genomic diagnostics organisation committed to translating advances in genomics into clinically meaningful healthcare solutions supported by clinical governance. Through its work in pharmacogenomics, precision oncology, genomic testing, clinical implementation, and international scientific collaboration, Precision Diagnostics aims to support safer, more personalised, and evidence-based patient care across Malaysia and the Asia-Pacific region.
